A large-scale study involving over 100,000 patients with gout has found that commonly prescribed urate-lowering medications, especially allopurinol, may significantly reduce the risk of heart attack and stroke when treatment goals are achieved.
The research indicates that patients who successfully brought their uric acid levels under control after starting therapy experienced a notable reduction in major cardiovascular events over a five-year period. Those who reached the recommended target of below 6 mg/dL within the first year saw the most pronounced benefits, highlighting the importance of timely and effective treatment.
Gout, a type of inflammatory arthritis caused by elevated uric acid levels, has long been associated with a higher risk of cardiovascular disease. The findings suggest that managing uric acid may not only help prevent painful flare-ups but could also play a role in protecting heart health.
The study observed that nearly all patients were treated with allopurinol, a widely used and cost-effective medication for lowering uric acid. Researchers noted that the greater the reduction in uric acid levels, the lower the likelihood of both gout complications and cardiovascular events.
While the results point to a strong association, experts caution that more research is needed to establish a direct cause-and-effect relationship. Still, the findings reinforce the importance of consistent treatment, proper dosing, and regular monitoring in people living with gout.
The study adds to growing evidence that controlling chronic inflammation, one of the hallmarks of gout, may have broader health benefits, particularly in reducing the risk of life-threatening conditions such as heart attack and stroke.
